Hoffman La Roche sees higher market share

Pharmaceutical company Hoffman La Roche saw its market share rise from 5.5% in the first half of 2004 to 6.77% at the end of the first half of 2005, according to Cegedim data. “The market share increase was generated by the higher sales of the company”s strategic products in the field of oncology, hepatitis and anaemia. At present, we rank second, and, in the long term, we will definitely be among the top three companies,” said Dan Zamonea, general manager of the company. The company posted sales worth 76.08 million euros during the July 2004-June 2005 period. The budget Hoffman La Roche has earmarked for investments this year amounts to 1 million Swiss francs (about 650,000 euros). “In Romania, the company invests in research. We also invest in clinical and hepatitis studies,” Zamonea also said. The company has been present in Romania for ten years and operates in top therapeutic sectors, virusology, oncology, obesity treatments and transplants. Early this year, Hoffman”s over-the-counter drugs were transferred to Bayer”s portfolio, in the wake of a transaction worth more than two billion euros. At the same time, the group carries local production programmes with Romanian firms, such as Cluj-based Terapia. ZF